review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Mario J Garcia | |
Constantine E Kosmas | |||
Andreas Sourlas | |||
Delia Silverio | |||
Eliscer Guzman | |||
Peter D Montan | |||
P2860 | cites work | Leukotrienes as modifiers of preclinical atherosclerosis? | Q27025129 |
Hydroxychloroquine for autoimmune diseases | Q28066201 | ||
Colchicine--Update on mechanisms of action and therapeutic uses | Q28082473 | ||
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis | Q28205296 | ||
Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis | Q28709376 | ||
Toward understanding interfacial activation of secretory phospholipase A2 (PLA2): membrane surface properties and membrane-induced structural changes in the enzyme contribute synergistically to PLA2 activation | Q30447476 | ||
Phospholipase A(2) enzymes in metabolic and cardiovascular diseases | Q33773427 | ||
Anti-inflammatory therapies for cardiovascular disease | Q34137872 | ||
Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers. | Q34151396 | ||
Phospholipase A(2) in vascular disease | Q34339322 | ||
Cytokines in atherosclerosis: pathogenic and regulatory pathways | Q34511711 | ||
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice | Q34598093 | ||
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 | ||
Methotrexate in atherogenesis and cholesterol metabolism | Q34757801 | ||
Endothelial function testing as a biomarker of vascular disease | Q35569232 | ||
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
Activin A and follistatin in systemic inflammation | Q35903331 | ||
A meta-analysis of proinflammatory cytokines in chronic heart failure | Q36057476 | ||
Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients | Q36877859 | ||
Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis | Q36964861 | ||
Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages | Q37008144 | ||
Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study | Q37153680 | ||
Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims | Q37308677 | ||
Activin, neutrophils, and inflammation: just coincidence? | Q38079493 | ||
Inflammation in coronary artery disease. | Q38179830 | ||
Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease | Q38265002 | ||
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. | Q38375421 | ||
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial | Q38424365 | ||
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial | Q38441000 | ||
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 | ||
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 | ||
Association of neutrophils and future cardiovascular events in patients with peripheral artery disease | Q40425085 | ||
Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein | Q41098875 | ||
Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications | Q41921823 | ||
Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction. | Q42033846 | ||
C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle | Q44382946 | ||
From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation | Q44711070 | ||
Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. | Q44878173 | ||
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
Potential anti-inflammatory role of activin A in acute coronary syndromes | Q44984913 | ||
Low-dose colchicine for secondary prevention of cardiovascular disease | Q46245044 | ||
C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction | Q46656237 | ||
Neutrophil count and infarct size in patients with acute myocardial infarction. | Q47409029 | ||
Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study | Q47620876 | ||
The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients | Q49787347 | ||
Increased activin A levels in prediabetes and association with carotid intima-media thickness: a cross-sectional analysis from I-Lan Longitudinal Aging Study. | Q55457462 | ||
Hydroxychloroquine: An old drug with new relevance | Q56379263 | ||
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease | Q57243317 | ||
Platelets in atherosclerosis | Q63916904 | ||
Leukotrienes | Q81542824 | ||
Activin A and cardiovascular disease in type 2 diabetes mellitus | Q83207389 | ||
Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome | Q84127561 | ||
Baseline leukocyte count and acute coronary syndrome: predictor of adverse cardiac events, long and short-term mortality and association with traditional risk factors, cardiac biomarkers and C-reactive protein | Q85170105 | ||
Activin A in Mammalian Physiology | Q90424447 | ||
The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease | Q90789713 | ||
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events | Q92980641 | ||
P433 | issue | 7 | |
P304 | page(s) | 147 | |
P577 | publication date | 2019-04-01 | |
P1433 | published in | Annals of Translational Medicine | Q26842362 |
P1476 | title | Anti-inflammatory therapy for cardiovascular disease. | |
P478 | volume | 7 |
Q94571766 | Risk factors for cardiovascular disease from a population-based screening study in Tianjin, China: a cohort study of 36,215 residents |
Q89978075 | Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis |
Q89831534 | Sweet and Sticky: Selective Recruitment of Monocyte Subsets by Endothelial N-Glycans |
Q89640159 | The atheroprotective roles of heart-protecting musk pills against atherosclerosis development in apolipoprotein E-deficient mice |
Q98186313 | The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome |
Search more.